Veronica Sanchez Bulis is VP & Controller at Lyell Immunopharma, Inc. (LYEL). They have made 5 open-market trades across 1 company since 2025, most recently 2026-08-10.
CIK 0002095702
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LYEL | 14,799 | $120K |
Shares reported on the most recent Form 4, priced at the 2026-08-11 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LYEL | SELL | 2026-08-10 | 2026-08-11 | $14.34 | $9K | +7.4% | -14.4% | — |
| LYEL | SELL | 2026-05-11 | 2026-06-15 | $18.91 | $4K | -8.2% | +11.1% | -12.4% |
| LYEL | SELL | 2026-02-10 | 2026-02-11 | $23.12 | $6K | -5.5% | -13.0% | -21.2% |
| LYEL | SELL | 2025-12-24 | 2026-01-06 | $35.80 | $74K | -8.3% | -12.6% | -15.6% |
| LYEL | SELL | 2025-11-10 | 2025-11-12 | $16.10 | $4K | +33.6% | +102.7% | +39.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.